Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer

被引：11

作者：

Zhong, Wenjing ^{[1
,2
]}

Yang, Yaping ^{[1
,2
]}

Zhang, Ailing ^{[3
]}

Lin, Wanyi ^{[1
,2
]}

Liang, Gehao ^{[1
,2
]}

Ling, Yun ^{[1
,2
]}

Zhong, Jiajie ^{[4
]}

Yong, Juanjuan ^{[4
]}

Liu, Zihao ^{[1
,2
]}

Tian, Zhenluan ^{[1
,2
]}

Lin, Qun ^{[1
,2
]}

Luo, Qing ^{[1
,2
]}

Li, Yangyang ^{[4
]}

Gong, Chang ^{[1
,2
]}

机构：

[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, 107 Yanjiang West Rd, Guangzhou 510120, Peoples R China

[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Dept Breast Surg, 107 Yanjiang West Rd, Guangzhou 510120, Peoples R China

[3] Dongguan City Peoples Hosp, Dept Breast Surg, Dongguan, Peoples R China

[4] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pathol, Guangzhou, Peoples R China

来源：

BREAST CANCER | 2020年 / 27卷 / 06期

基金：

国家重点研发计划;

关键词：

TOP2A; HER2; Anthracycline; Survival; TOPOISOMERASE-II-ALPHA; GENE AMPLIFICATION; ADJUVANT CHEMOTHERAPY; PROTEIN; TRASTUZUMAB; EXPRESSION; THERAPY;

D O I：

10.1007/s12282-020-01142-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background We aim to evaluate the prognostic and predictive value of TOP2A and HER2 expression in T1N0 breast cancer patients. Methods 299 cases with T1N0 breast cancer were obtained from the Oncomine database (Cohort 1) and 963 of T1N0 breast cancer patients from Sun Yat-sen Memorial Hospital (Cohort 2) were retrospectively enrolled. Kaplan-Meier product was applied to estimate survival curve. Cox proportional hazard models was used to identify prognostic factors. We used PSM (propensity score matching) to balance clinicopathologic characteristics among four groups of different HER2/TOP2A status. Survival between groups and chemotherapy regimens were analyzed, before and after PSM. Results In Cohort 1, we found that the group with HER2+ and higher expression of TOP2A mRNA was associated with poor breast cancer-specific survival (BCSS) compared to the group of HER2- with lower expression of TOP2A mRNA. In Cohort 2, HER2+ patients with higher TOP2A protein expression had greater risk of recurrence and distant recurrence compared to HER2- patients with lower expression of TOP2A protein. Among the patients who developed both HER2+ and higher expression of TOP2A protein and received chemotherapy, patients who received an anthracycline-based regimen had a significantly better recurrence-free survival (RFS) than those with a non-anthracycline-based regime. Conclusion Patients with both HER2+ and high expression level of TOP2A protein predicts poor prognosis in T1N0 breast cancer patients. Patients with double positive for TOP2A protein and HER2 may benefit from anthracycline-based regimens.

引用

页码：1147 / 1157

页数：11

共 31 条

[1] The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer [J].